The Association of Clinical Research Organizations (ACRO), which represents the clinical research organization (CRO) industry to regulators, biopharmaceutical clients, policy makers and the public in the U.S. and worldwide, today announced the addition of two new member companies to the association as well as the appointment of a new representative to the ACRO Board of Directors. Clinilabs, Inc., a specialty CRO that provides a full portfolio of services focused on the development of central nervous system and cardiovascular therapeutics, has joined ACRO as an associate member. ReSearch Pharmaceutical Services, Inc. (RPS), a leading provider of comprehensive global Phase I-IV clinical development solutions, has joined at the regular member level. In addition, Daniel M. Perlman, Chairman and CEO of RPS, has been named to the ACRO Board of Directors. All regular members of ACRO are represented with a seat on the association’s Board. “I am extremely pleased to welcome Clinilabs and RPS as new members of ACRO,” said David Spaight, ACRO Chair and President of MDS Pharma Services. “Their involvement will enhance the association’s ability to represent the CRO industry broadly to government officials, research sponsors, patient groups, and others international stakeholders. We invite all CROs to consider membership in our industry’s trade association.”“The association looks forward to the addition of Mr. Perlman to our Board of Directors,” added ACRO Executive Director Doug Peddicord, Ph.D. “The leadership and vision of the ACRO Board is instrumental in driving our efforts to advance the CRO industry and to promote CROs as strategic partners in drug development.”
